Orchestra BioMed Holdings (OBIO) Depreciation & Amortization - Total (2024 - 2025)
Orchestra BioMed Holdings (OBIO) reported Depreciation & Amortization - Total of $81000.0 for Q3 2025, up 6.58% year-over-year from $76000.0 in Q3 2024, and little changed on a QoQ basis from $81000.0 in Q2 2025.
Orchestra BioMed Holdings (OBIO) has 2 years of Depreciation & Amortization - Total data on file, last reported at $81000.0 in Q3 2025.
- Quarterly Depreciation & Amortization - Total rose 6.58% year-over-year to $81000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $162000.0 (down 48.9% YoY) and the FY2024 annual result came in at $308000.0, up 7.32% from the prior year.
- Depreciation & Amortization - Total was little changed at $81000.0 in Q3 2025 per OBIO's latest filing, from $81000.0 in the prior quarter.
- Across five years, Depreciation & Amortization - Total topped out at $84000.0 in Q4 2024 and bottomed at $74000.0 in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 74,000.00 |
| Mar 31, 2024 | 74,000.00 |